Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure

Next Previous
X
Search
Trial Profile

A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toripalimab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms POLARIS-01
  • Sponsors Shanghai Junshi Biosciences

    • Most Recent Events

    • 06 Jan 2025 According to a Junshi Biosciences media release, in December 2018, toripalimab was conditionally approved by the NMPA for the treatment of unresectable or metastatic melanoma that has previously received systemic systemic therapy, becoming the first domestic PD-1-targeting monoclonal antibody drug approved for marketing in China based on this study.
    • 03 Jun 2024 Results of POLARIS-01 Phase II Trial presented in the Oncologist
    • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top